Browse News
Filter News
Found 70 articles
-
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting
3/28/2024
Vaxxinity, Inc. announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado.
-
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates
3/27/2024
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
-
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients
3/7/2024
Vaxxinity, Inc. announced positive clinical data from its UB-312 program in Parkinson’s disease presented by Jean-Cosme Dodart, PhD, SVP of Research at Vaxxinity in an oral session at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease, held virtually and in Lisbon, Portugal from March 5 to March 9, 2024.
-
Amprion's αSyn Seed Amplification Assay (αS-SAA) Highlighted in 10 Presentations at AD/PD™ 2024 International Conference
3/4/2024
Amprion is pleased to announce its presence at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon, Portugal on March 5-9.
-
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
2/15/2024
Vaxxinity, Inc., a U.S. company pioneering the development of a new class of medicines, announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol in non-human primates.
-
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024
2/13/2024
Vaxxinity, Inc. today announced it will present clinical data from its UB-312 program in Parkinson’s disease and preclinical data from its anti-tau program in Alzheimer’s disease at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD 2024) , taking place March 5-9, 2024.
-
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida
1/30/2024
Vaxxinity, Inc. today announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases.
-
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
1/18/2024
Vaxxinity, Inc., a U.S. company pioneering the development of a new class of medicines, announced a collaboration with the University of Central Florida to advance space medicine research.
-
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
1/3/2024
Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024, at 10:30am PST.
-
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
11/8/2023
Vaxxinity, Inc. today reported financial results for the third quarter ended September 30, 2023, and provided a corporate update.
-
While the trial was designed to test safety and not efficacy, patients treated with Araclon Biotech’s experimental ABvac40 vaccine saw a 38% drop in disease progression compared to placebo.
-
Vaxxinity to Present at Upcoming Investor Conferences in September 2023
8/29/2023
Vaxxinity, Inc., a U.S. company pioneering the development of a new class of medicines, announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present and participate in meetings at the following investor conferences in New York in September.
-
Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
8/22/2023
Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the appointment of M. Christina Yi to Chief Technology Officer effective August 21, 2023.
-
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
8/10/2023
Vaxxinity, Inc. announced the print publication of Phase 2a clinical trial data in The Lancet’s eBioMedicine, stating that UB-311 “was safe and well-tolerated,” with early clinical data demonstrating a trend for slowing cognitive decline in mild Alzheimer’s disease.
-
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
8/9/2023
Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
-
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
7/27/2023
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, announced that Peter Powchik, M.D., will join Vaxxinity’s leadership team as Executive Vice President, Global Scientific Director starting October 1, 2023.
-
Vaxxinity Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson’s Patients
7/17/2023
Vaxxinity, Inc. today announced new data from a Phase 1 clinical trial demonstrating that antibodies derived from its investigational immunotherapeutic for Parkinson’s disease (PD), UB-312, slows seeding of alpha-synuclein (aSyn) in cerebrospinal fluid (CSF) of patients with PD as demonstrated using multiple target engagement assays.
-
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease
6/22/2023
Vaxxinity, Inc. today announced positive results from Part B of its Phase 1 clinical trial of UB-312, an investigational vaccine for Parkinson’s disease (PD), demonstrating UB-312 was well-tolerated and induced anti-alpha-synuclein (aSyn) antibody responses in participants with early PD, meeting the primary objectives of the trial.
-
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update
5/9/2023
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
-
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
3/28/2023
Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that members of its leadership team will present data on investigational vaccines for COVID-19 and neurodegenerative diseases at three upcoming scientific and medical conferences in April.